Mesoblast, the local biotech developing treatments for cardiovascular disease and back pain, is no stranger to the capital markets. Over the weekend, it had Bell Potter lining up another cash injection.
Street Talk understands Mesoblast started the raising talks at $US25 million ($37 million) and at a 85¢-per-share price marker. Investors, however, expect the business to try to build early interest into a bigger capital raising.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
